Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Notes Payables (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Notes Payables for 12 consecutive years, with $1.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Notes Payables rose 348.07% year-over-year to $1.4 million, compared with a TTM value of $1.4 million through Sep 2025, up 348.07%, and an annual FY2024 reading of $1.1 million, up 0.99% over the prior year.
  • Notes Payables was $1.4 million for Q3 2025 at China Pharma Holdings, roughly flat from $1.4 million in the prior quarter.
  • Across five years, Notes Payables topped out at $4.6 million in Q3 2022 and bottomed at $315428.0 in Q3 2024.
  • Average Notes Payables over 5 years is $1.7 million, with a median of $1.3 million recorded in 2021.
  • The sharpest move saw Notes Payables tumbled 84.44% in 2024, then soared 348.07% in 2025.
  • Year by year, Notes Payables stood at $1.2 million in 2021, then surged by 222.25% to $3.8 million in 2022, then plummeted by 70.16% to $1.1 million in 2023, then rose by 0.99% to $1.1 million in 2024, then grew by 23.44% to $1.4 million in 2025.
  • Business Quant data shows Notes Payables for CPHI at $1.4 million in Q3 2025, $1.4 million in Q2 2025, and $1.2 million in Q1 2025.